Organization | The Methodist Hospital System

The Methodist Hospital System Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4

Organization Overview

First Clinical Trial

2011

NCT01446094

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2016

Timeline

NOW

Now

Alternative names

Angel Augusto Rodriguez, MD | Dipan Shah | Joshua Swan

Active Ingredients

Drugs in Phase 4 Trials (1)

regadenoson (lexiscan) (1 trial)

Drugs in Phase 2 Trials (5)

docetaxel (taxotere) (2 trials)

doxorubicin (Doxil) (1 trial)

epirubicin (ellence) (1 trial)

ixabepilone (ixempra) (1 trial)

paclitaxel (taxol) (1 trial)

Drugs in Phase 1 Trials (3)

amlodipine (norvasc) (1 trial)

Filgrastim (neupogen) (1 trial)

l-nmma (1 trial)

Drugs in Other Trials (4)

chlorhexidine (hibitane) (1 trial)

gadopenteate dimeglumine (magnevist) (1 trial)

gadoteric acid (Dotarem) (1 trial)

hydroxytyrosol (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 2)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Myocardial Ischemia (Phase 4)

Triple Negative Breast Neoplasms (Phase 1)

Overview

Highest Phase: Phase 4
# of Trials: 6
# of Trial APIs: 13